Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005240 | 0.86 | GAA (0.71) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL14202808 | 0.85 | POLB (0.69) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL9181550 | 0.85 | POLB (0.69) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL17680989 | 0.84 | KMT2A (0.77) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL28799085 | 0.83 | GAA (0.63) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL8773849 | 0.83 | MEN1 (0.67) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL13752250 | 0.82 | HDAC3 (0.64) | POLBALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL1068813 | 0.82 | GAA (0.65) | GAAPOLBTSHRALDH1A1LMNA | |
| SCHEMBL11578349 | 0.81 | HPGD (0.65) | GAAPOLBALDH1A1LMNAMEN1 | |
| SCHEMBL12971593 | 0.81 | POLB (0.58) | GAAPOLBTSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| EP-0310732-B1 | PROCESS FOR THE PREPARATION OF N-ACYL-N-ALKYL-2,6-DIALKYL-3-CHLOROANILINES | CIBA-GEIGY AG (CH) | 1992-03-11 | — | — | EP | disclosed |
| EP-0310732-A1 | Process for the preparation of N-acyl-N-alkyl-2,6-dialkyl-3-chloroanilines | CIBA-GEIGY AG (CH) | 1989-04-12 | — | — | EP | disclosed |
| EP-0284555-A1 | Process for the preparation of N-acyl-N-(oxazoliden-2-on-3-yl)-2,6-dialkyl-3-chloroanilines | CIBA-GEIGY AG (CH) | 1988-09-28 | — | — | EP | disclosed |
| US-4721797-A | Process for the preparation of N-acyl-N-alkyl-2,6-dialkyl-3-chloroanilines | CIBA-GEIGY CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | GAA 3489/4885POLB 3476/4885TSHR 3829/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | GAA 55/4885POLB 1012/4885TSHR 4552/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | GAA 55/4885POLB 1012/4885TSHR 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.